ELI LILLY AND COMPANY Debt Instrument, Interest Rate, Stated Percentage
ELI LILLY AND COMPANY (LLY) had Debt Instrument, Interest Rate, Stated Percentage of 6.55% as of 2010-12-31, per its 10-K filed 2011-02-22.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentInterestRateStatedPercentage · last filed 2011-02-22
- 2010-12-31: Debt Instrument, Interest Rate, Stated Percentage 6.55%.
| Period end | Debt Instrument, Interest Rate, Stated Percentage |
|---|---|
| 2010-12-31 | 6.55% 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |